IRIDEX Corporation (IRIX)
NASDAQ: IRIX · Real-Time Price · USD
1.170
+0.050 (4.46%)
Aug 15, 2025, 10:30 AM - Market open
IRIDEX Revenue
IRIDEX had revenue of $13.57M in the quarter ending June 28, 2025, with 7.44% growth. This brings the company's revenue in the last twelve months to $49.74M, up 0.09% year-over-year. In the year 2024, IRIDEX had annual revenue of $48.67M, down -6.17%.
Revenue (ttm)
$49.74M
Revenue Growth
+0.09%
P/S Ratio
0.38
Revenue / Employee
$534,882
Employees
93
Market Cap
19.88M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 28, 2024 | 48.67M | -3.20M | -6.17% |
| Dec 30, 2023 | 51.87M | -5.10M | -8.96% |
| Dec 31, 2022 | 56.97M | 3.07M | 5.69% |
| Jan 1, 2022 | 53.90M | 17.56M | 48.30% |
| Jan 2, 2021 | 36.35M | -7.10M | -16.34% |
| Dec 28, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 29, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 2, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
IRIX News
- 2 days ago - IRIDEX Corporation (IRIX) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 2 days ago - Iridex Reports Second Quarter 2025 Financial Results - GlobeNewsWire
- 7 weeks ago - Iridex Announces First Patient Enrolled in an Independent Landmark Investigator-Led UK Study Evaluating MicroPulse® Technology as an Adjunct to anti-VEGF Therapy for Diabetic Macular Edema - GlobeNewsWire
- 3 months ago - IRIDEX Corporation, Inc. (IRIX) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Iridex Reports First Quarter 2025 Financial Results - GlobeNewsWire
- 3 months ago - IRIDEX Changes Course - Seeking Alpha
- 3 months ago - Iridex to Report First Quarter 2025 Financial Results on May 13, 2025 - GlobeNewsWire
- 4 months ago - IRIDEX Corporation (IRIX) Strategic Vision Conference Call (Transcript) - Seeking Alpha